(BASED ON OTE) BUY @ 41.20-41.80
(MAIN OBJECTIVE )TARGET 1 @ 45.20
(SECONDARY OBJECTIVE TRADE AT OWN RISK) TARGET 2 @ 47.50
(SECONDARY OBJECTIVE TRADE AT OWN RISK) TARGET 3 @ 50.20
STOP LOSS: DETERMINE HOW MUCH YOU ARE WILLING TO RISK OF YOUR OWN CAPITAL AND PLACE STOP LOSS ACCORDINGLY, REMEMBER YOU ARE TO RISK A MAXIMUM OF ONLY 3% OF YOUR CAPITAL, AND THAT ONLY...
Goldman Sachs trades laterally on both long term and short term basis.
On long term basis price has recently failed uptrend borders, marked by upper 1st standard deviations from 10 and 5-year means - thus entering lateral territory within the 1st standard deviations.
On short term basis price has failed to enter a downtrend on 1-year basis by holding within 1st...
Two highlights from the past week /after the #FOMC and #BOJ/:
Imo ... individual investors are out of the market, on the indices is playing Goldman Sachs orchestra. How much longer??
Dr. Glynn Wilson the Chairman and CEO of TapImmune will present at the Sachs Associates' 3rd Annual Bio Partnering & Investment Forum on 2/23. The company had Phase I trials completed with 20 of 21 cancer patients reacting with positive immune responses. Additionally, TapImmune has a very deep drug pipeline in multipe indications for upcoming Phase II trials....